Gilead Sciences, Inc. $GILD Shares Bought by CW Advisors LLC

CW Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 309.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 100,734 shares of the biopharmaceutical company’s stock after purchasing an additional 76,119 shares during the quarter. CW Advisors LLC’s holdings in Gilead Sciences were worth $11,169,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. Rothschild Investment LLC lifted its stake in shares of Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 84 shares during the period. Archer Investment Corp increased its position in shares of Gilead Sciences by 1.2% during the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after purchasing an additional 87 shares during the period. EPG Wealth Management LLC raised its stake in shares of Gilead Sciences by 2.0% in the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after buying an additional 89 shares in the last quarter. Southland Equity Partners LLC lifted its holdings in shares of Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 92 shares during the period. Finally, Putney Financial Group LLC lifted its holdings in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Daiwa Capital Markets increased their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Truist Financial initiated coverage on shares of Gilead Sciences in a research report on Monday, November 24th. They issued a “buy” rating and a $140.00 price target on the stock. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $130.65.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $122.62 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The firm’s 50 day simple moving average is $120.76 and its 200-day simple moving average is $115.14. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The company has a market cap of $152.13 billion, a P/E ratio of 19.01, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter last year, the business posted $2.02 EPS. The company’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Activity

In related news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the transaction, the executive vice president directly owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 135,757 shares of company stock valued at $16,616,127 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.